Medical device and MedTech insights, news, tips and more

Zimmer Biomet announces acquisition of MedTech – maker of the Rosa Robotic Spine System

July 18, 2016

Zimmer Biomet

Zimmer BiometZimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (Zimmer Biomet), a global leader in musculoskeletal healthcare, and Medtech SA (Euronext, FR0010892950 – ROSA) (Medtech), a leading French medical technology company, today announced that, following the unanimous approval of both companies’ boards of directors, a wholly-owned subsidiary of Zimmer Biomet has acquired 1,406,151 Medtech shares, representing 58.77% of the outstanding share capital of Medtech, from Mr. Bertin Nahum, Newfund and certain other selling stockholders in a private transaction, as well as all outstanding convertible bonds and warrants previously issued by Medtech to Ally Bridge Group.

The shares were acquired at a price of €50.00 per share, the convertible bonds at a price of €50.03 per convertible bond and the warrants at a price of €17.17 per warrant.

In accordance with French law, a wholly-owned subsidiary of Zimmer Biomet will launch, as soon as possible, an all-cash simplified tender offer to acquire the remaining outstanding shares of Medtech for the same price per share (€50.00). The draft documentation relating to the public offer will include the terms and conditions of the offer and will be subject to review by the Autorité des marchés financiers (AMF). The offer will only be opened after the AMF has granted its clearance. The tender offer would be followed by a squeeze out of minority shareholders if the conditions are met at the end of the offer. Ledouble (represented by Mr. Olivier Cretté) has been appointed as independent expert pursuant to art. 261-1 I and II of the AMF General Regulation.

In connection with the change in control of Medtech, the following members of Medtech’s board of directors have resigned: Mr. Frank Yu, Mr. Fernand Badano and Mr. Eric Briole. The resulting vacancies on Medtech’s board of directors, as well as a fourth vacancy created earlier this year following the resignation of a representative of Newfund, have been filled by four representatives of Zimmer Biomet.

Subject to the terms of the agreement between the parties, Zimmer Biomet intends to continue operations of Medtech at the current headquarters in Montpellier, and also intends that this location become a center of excellence for the purchaser’s robotic development activities. Zimmer Biomet intends that Bertin Nahum, current CEO of Medtech, will lead the purchaser’s robotic development activities.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit or follow Zimmer Biomet on Twitter at

About Medtech

Founded in 2002 by Bertin Nahum and based in Montpellier, France, Medtech is a leader in the design, development and marketing of innovative robotic applications to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less invasive treatment.

Read Full Release – Source: Medtech SA (via Public) / ZIMMER BIOMET TO ACQUIRE MEDTECH

07/18/2016 | Press release | Distributed by Public on 07/18/2016 14:27

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.